FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2972624365> ?p ?o ?g. }

• W2972624365 endingPage "1594" @default.
• W2972624365 startingPage "1594" @default.
• W2972624365 abstract "Background: Since the introduction of tyrosine kinase inhibitors (TKI), most patients (pts) with chronic myeloid leukemia (CML) have a favorable outcome with their initial therapy. However, some pts experience resistance or intolerance. Second generation TKI dasatinib, nilotinib and bosutinib are effective (and approved) for pts with failure to one prior TKI. In the absence of specific mutations or patient comorbidities driving the selection of a specific TKI, selecting the next TKI remains at the physician discretion, especially in the lack of randomized data comparing 2nd generation TKI. Methods: We analyzed the outcomes of 621 consecutive patients with CML treated at a single institution with 2nd generation TKI in the 2nd line following failure of frontline TKI. For this analysis we focused on the 572 pts that received dasatinib, nilotinib or bosutinib as 2nd line TKI (not including 49 pts treated with ponatinib, imatinib or investigational TKI). Results: The median age at diagnosis was 47 years (range, 12-86) and 49% were male. 516 pts received TKI as frontline treatment and 105 had other therapies (interferon, chemotherapy) prior to TKI. Pts were switched to a 2nd generation TKI for resistance (n=337; 54%) or intolerance (n= 279; 45%). The median time from diagnosis to start of 2nd line TKI was 32 mo (0 to 206 mo). Dasatinib, nilotinib and bosutinib were used as 2nd line TKI in 338 (54%), 194 (31%), and 40 (6%) pts, respectively. Overall, out of 572 pts who received one of these three TKIs, 401 had cytogenetic evaluation of which 323 (81%) achieved major cytogenetic response (34 (8%) partial (PCyR) and 289 (72%) complete (CCyR)). Out of 428 who had a molecular evaluation, 75% achieved molecular response (94 (18%) MMR, 52 (6%) MR4, 217 (51%) MR4.5). The rates of major cytogenetic response (MCyR) were, with dasatinib 85% (76% CCyR), nilotinib 76% (70% CCyR), and bosutinib 67% (50% CCyR) (p=0.015). Rates of molecular response (MMR or better) were with dasatinib 72% (55% MR4.5), nilotinib 65% (46% MR4.5), and bosutinib 55% (39% MR4.5), (p=0.07). At a median follow-up from diagnosis of 96 mo (range, 4-283), 39 (7%) pts transformed either to accelerated (n=26, 5%) or to blast phase (n=13, 2%) while on 2nd line TKI. Median overall survival (OS) and transformation-free survival (TFS) were not reached and the median event-free survival (EFS) was 121 mo. Seven-year probabilities of OS, TFS and EFS were 66%, 91% and 55%, respectively. Higher OS, TFS, and EFS were found in patients who received frontline TKI (7-yr 70%, 92% and 59%, respectively) vs those who failed another treatment prior to any TKI (49%, 83%, and 38%, respectively) (p Conclusion: This analysis shows that dasatinib, nilotinib and bosutinib remain largely effective in inducing cytogenetic and molecular response when used as a 2nd line TKI with similar OS, TFS and EFS in the overall pts population. A multivariate analysis to identify predictors of long-term outcome, including specific TKI as a variable, is ongoing. Disclosures Kantarjian: Novartis: Research Funding; Bristol-Meyers Squibb: Research Funding; Amgen: Research Funding; ARIAD: Research Funding; Delta-Fly Pharma: Research Funding; Pfizer: Research Funding. DiNardo: Daiichi-Sankyo: Honoraria, Research Funding; Celgene: Honoraria, Research Funding; AbbVie: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; Agios: Honoraria, Research Funding. Daver: Bristol-Myers Squibb Company: Consultancy, Research Funding; Incyte Corporation: Honoraria, Research Funding; Pfizer Inc.: Consultancy, Research Funding; Jazz: Consultancy; Novartis Pharmaceuticals Corporation: Consultancy; Immunogen: Research Funding; Kiromic: Research Funding; Otsuka America Pharmaceutical, Inc.: Consultancy; Daiichi-Sankyo: Research Funding; Sunesis Pharmaceuticals, Inc.: Consultancy, Research Funding; Karyopharm: Consultancy, Research Funding. Pemmaraju: Incyte Corporation: Consultancy, Honoraria; cellectis: Research Funding; novartis: Consultancy, Honoraria, Research Funding; abbvie: Research Funding; roche diagnostics: Consultancy, Honoraria; affymetrix: Research Funding; LFB: Consultancy, Honoraria; stemline: Consultancy, Honoraria, Research Funding. Burger: Novartis: Consultancy, Honoraria, Other: Travel, Accommodations, Expenses; Janssen: Consultancy, Honoraria, Other: Travel, Accommodations, Expenses; Pharmacyclics LLC, an AbbVie Company: Consultancy, Honoraria, Other: Travel, Accommodations, Expenses, Research Funding; TG Therapeutics: Consultancy, Honoraria, Other: Travel, Accommodations, Expenses, Research Funding; Gilead: Consultancy, Honoraria, Other: Travel, Accommodations, Expenses, Research Funding. Jabbour: Bristol-Myers Squibb: Consultancy. Cortes: Pfizer: Consultancy, Research Funding; BMS: Consultancy, Research Funding; ImmunoGen: Consultancy, Research Funding; Novartis Pharmaceuticals Corporation: Consultancy, Research Funding; ARIAD: Consultancy, Research Funding; Sun Pharma: Research Funding; Teva: Research Funding." @default.
• W2972624365 created "2019-09-19" @default.
• W2972624365 creator A5000750846 @default.
• W2972624365 creator A5010786159 @default.
• W2972624365 creator A5015101485 @default.
• W2972624365 creator A5020340537 @default.
• W2972624365 creator A5022647201 @default.
• W2972624365 creator A5028845635 @default.
• W2972624365 creator A5035605515 @default.
• W2972624365 creator A5048853852 @default.
• W2972624365 creator A5049385583 @default.
• W2972624365 creator A5055045706 @default.
• W2972624365 creator A5058755419 @default.
• W2972624365 creator A5061026876 @default.
• W2972624365 creator A5069285537 @default.
• W2972624365 creator A5080068726 @default.
• W2972624365 creator A5084290698 @default.
• W2972624365 creator A5088307376 @default.
• W2972624365 creator A5089428686 @default.
• W2972624365 creator A5090435894 @default.
• W2972624365 date "2017-12-07" @default.
• W2972624365 modified "2023-10-15" @default.
• W2972624365 title "Long-Term Outcome of CML Patients Treated with Second-Generation Tyrosine Kinase Inhibitors in the Second Line: A Single Center Experience" @default.
• W2972624365 doi "https://doi.org/10.1182/blood.v130.suppl_1.1594.1594" @default.
• W2972624365 hasPublicationYear "2017" @default.
• W2972624365 type Work @default.
• W2972624365 sameAs 2972624365 @default.
• W2972624365 citedByCount "0" @default.
• W2972624365 crossrefType "journal-article" @default.
• W2972624365 hasAuthorship W2972624365A5000750846 @default.
• W2972624365 hasAuthorship W2972624365A5010786159 @default.
• W2972624365 hasAuthorship W2972624365A5015101485 @default.
• W2972624365 hasAuthorship W2972624365A5020340537 @default.
• W2972624365 hasAuthorship W2972624365A5022647201 @default.
• W2972624365 hasAuthorship W2972624365A5028845635 @default.
• W2972624365 hasAuthorship W2972624365A5035605515 @default.
• W2972624365 hasAuthorship W2972624365A5048853852 @default.
• W2972624365 hasAuthorship W2972624365A5049385583 @default.
• W2972624365 hasAuthorship W2972624365A5055045706 @default.
• W2972624365 hasAuthorship W2972624365A5058755419 @default.
• W2972624365 hasAuthorship W2972624365A5061026876 @default.
• W2972624365 hasAuthorship W2972624365A5069285537 @default.
• W2972624365 hasAuthorship W2972624365A5080068726 @default.
• W2972624365 hasAuthorship W2972624365A5084290698 @default.
• W2972624365 hasAuthorship W2972624365A5088307376 @default.
• W2972624365 hasAuthorship W2972624365A5089428686 @default.
• W2972624365 hasAuthorship W2972624365A5090435894 @default.
• W2972624365 hasConcept C121608353 @default.
• W2972624365 hasConcept C126322002 @default.
• W2972624365 hasConcept C143998085 @default.
• W2972624365 hasConcept C2777413986 @default.
• W2972624365 hasConcept C2777583451 @default.
• W2972624365 hasConcept C2778208673 @default.
• W2972624365 hasConcept C2778729363 @default.
• W2972624365 hasConcept C2778820342 @default.
• W2972624365 hasConcept C2779536868 @default.
• W2972624365 hasConcept C2780381907 @default.
• W2972624365 hasConcept C71924100 @default.
• W2972624365 hasConceptScore W2972624365C121608353 @default.
• W2972624365 hasConceptScore W2972624365C126322002 @default.
• W2972624365 hasConceptScore W2972624365C143998085 @default.
• W2972624365 hasConceptScore W2972624365C2777413986 @default.
• W2972624365 hasConceptScore W2972624365C2777583451 @default.
• W2972624365 hasConceptScore W2972624365C2778208673 @default.
• W2972624365 hasConceptScore W2972624365C2778729363 @default.
• W2972624365 hasConceptScore W2972624365C2778820342 @default.
• W2972624365 hasConceptScore W2972624365C2779536868 @default.
• W2972624365 hasConceptScore W2972624365C2780381907 @default.
• W2972624365 hasConceptScore W2972624365C71924100 @default.
• W2972624365 hasLocation W29726243651 @default.
• W2972624365 hasOpenAccess W2972624365 @default.
• W2972624365 hasPrimaryLocation W29726243651 @default.
• W2972624365 hasRelatedWork W2594958377 @default.
• W2972624365 hasRelatedWork W2603087458 @default.
• W2972624365 hasRelatedWork W2784880685 @default.
• W2972624365 hasRelatedWork W2785018325 @default.
• W2972624365 hasRelatedWork W2898975580 @default.
• W2972624365 hasRelatedWork W2906776252 @default.
• W2972624365 hasRelatedWork W2908849319 @default.
• W2972624365 hasRelatedWork W2912399698 @default.
• W2972624365 hasRelatedWork W2921168312 @default.
• W2972624365 hasRelatedWork W2927166793 @default.
• W2972624365 hasRelatedWork W2950777189 @default.
• W2972624365 hasRelatedWork W2966756494 @default.
• W2972624365 hasRelatedWork W2972830127 @default.
• W2972624365 hasRelatedWork W2977209068 @default.
• W2972624365 hasRelatedWork W2977426574 @default.
• W2972624365 hasRelatedWork W2980272413 @default.
• W2972624365 hasRelatedWork W2981023396 @default.
• W2972624365 hasRelatedWork W2989177065 @default.
• W2972624365 hasRelatedWork W3095806280 @default.
• W2972624365 hasRelatedWork W3148401066 @default.
• W2972624365 hasVolume "130" @default.
• W2972624365 isParatext "false" @default.
• W2972624365 isRetracted "false" @default.
• W2972624365 magId "2972624365" @default.
• W2972624365 workType "article" @default.